Alzheimer’s research is hot, but successful patient recruitment will determine its future

Key strategies for bringing more patients into the clinical trial fold.

By Kelly Bilodeau • Jan. 4, 2024

Pharma’s financial market will be a tale of two cities in 2024

What can the industry expect in 2024? Some bright spots, a few bumps and “immaculate disinflation.”

By Kelly Bilodeau • Jan. 4, 2024

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Why J&J rebranded its iconic logo

J&J’s refreshed identity provides insight into how and why pharma companies give themselves a makeover.

By Alexandra Pecci • Jan. 3, 2024

10 of our most read articles in 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

By Meagan Parrish • Dec. 22, 2023

Biopharma’s FTC headache deepens with guideline shifts years in the making

Closer scrutiny of pharma deals has made the M&A landscape trickier as a new approach seeks to expand the competitive arena.

By Michael Gibney • Dec. 21, 2023

What are pharma’s next blockbusters?

In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

By Kelly Bilodeau • Dec. 20, 2023

5 noteworthy pharma AI investments in 2023

The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.

By Alexandra Pecci • Dec. 19, 2023

Trends shaping the pharmaceutical industry in 2024

Advancements in cloud and AI technology will transform clinical trial efficiency and engagement.

By Seema Verma, SVP and GM, Oracle Life Sciences • Dec. 18, 2023

Study suggests PBMs are gaming pharmacy system to overcharge for drugs

Markups for generics can be as high as 7,000%, the researchers said.

By Alexandra Pecci • Dec. 15, 2023

The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them

Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.

By Michael Gibney • Dec. 14, 2023

A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

By Meagan Parrish • Dec. 13, 2023

What’s being done to prepare for the next pandemic?

Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.

By Kelly Bilodeau • Dec. 13, 2023

Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

By Michael Gibney • Dec. 12, 2023

Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

By Alexandra Pecci • Dec. 11, 2023

Oncology drugmakers seek the sweet spot between efficacy and tolerability

The FDA is now pushing companies to find the optimal dose early in development to minimize harm.

By Kelly Bilodeau • Dec. 11, 2023

Real Chemistry’s CEO on biopharma’s outlook in 2024

Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

By Michael Gibney • Dec. 7, 2023

4 historic FDA approvals from 2023

This year’s many firsts included a vaccine for RSV and a drug that slows Alzheimer’s disease.

By Alexandra Pecci • Dec. 6, 2023

The digital therapeutics revolution is here. Will payers play ball?

Apps, VR and more could play an increasingly vital role in the wider goals of creating value-based treatments — if the industry can get payers to sign on.

By Kelly Bilodeau • Dec. 5, 2023

The weight loss market looks unstoppable. How high could it go?

Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

By Kelly Bilodeau • Dec. 4, 2023

The fortunes and flops of pharma M&A

Hindsight offers a better perspective on why some deals are fruitful and others fail.

By Alexandra Pecci • Dec. 4, 2023

3 standout digital innovations in pharma this year

IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.

By Meagan Parrish • Dec. 1, 2023

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

By Jonathan Gardner • Nov. 29, 2023

Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help

A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.

By Kelly Bilodeau • Nov. 29, 2023

The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.

By Michael Gibney • Nov. 28, 2023

Biopharma’s top 5 IPOs of 2023 (so far)

Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

By Alexandra Pecci • Nov. 28, 2023